SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome - 05/04/21
Abstract |
Background |
Little is known about the relationships between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the respiratory virus responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic, and the upper respiratory tract (URT) microbiome.
Objective |
We sought to compare the URT microbiome between SARS-CoV-2–infected and –uninfected adults and to examine the association of SARS-CoV-2 viral load with the URT microbiome during COVID-19.
Methods |
We characterized the URT microbiome using 16S ribosomal RNA sequencing in 59 adults (38 with confirmed, symptomatic, mild to moderate COVID-19 and 21 asymptomatic, uninfected controls). In those with COVID-19, we measured SARS-CoV-2 viral load using quantitative reverse transcription PCR. We then examined the association of SARS-CoV-2 infection status and its viral load with the ⍺-diversity, β-diversity, and abundance of bacterial taxa of the URT microbiome. Our main models were all adjusted for age and sex.
Results |
The observed species index was significantly higher in SARS-CoV-2–infected than in –uninfected adults (β linear regression coefficient = 7.53; 95% CI, 0.17-14.89; P = .045). In differential abundance testing, 9 amplicon sequence variants were significantly different in both of our comparisons, with Peptoniphilus lacrimalis, Campylobacter hominis, Prevotella 9 copri, and an Anaerococcus unclassified amplicon sequence variant being more abundant in those with SARS-CoV-2 infection and in those with high viral load during COVID-19, whereas Corynebacterium unclassified, Staphylococcus haemolyticus, Prevotella disiens, and 2 Corynebacterium_1 unclassified amplicon sequence variants were more abundant in those without SARS-CoV-2 infection and in those with low viral load during COVID-19.
Conclusions |
Our findings suggest complex associations between SARS-CoV-2 and the URT microbiome in adults. Future studies are needed to examine how these viral-bacterial interactions can impact the clinical progression, severity, and recovery of COVID-19.
Il testo completo di questo articolo è disponibile in PDF.Key words : 16S rRNA sequencing, coronavirus, COVID-19, microbiome, nasal, nasopharynx, respiratory, SARS-CoV-2
Abbreviations used : ASV, COVID-19, LRT, SARS-CoV-2, URT
Mappa
This study is being submitted as an abstract to the American Thoracic Society International Conference 2021 (San Diego, Calif). |
|
This work was supported by funds from the National Institute of Allergy and Infectious Diseases (under award nos. R21AI142321, R21AI154016, and R21AI149262); the National Heart, Lung, and Blood Institute (under award nos. K23HL148638 and R01HL146401); and the Vanderbilt Technologies for Advanced Genomics Core (grant support from the National Institutes of Health under award nos. UL1RR024975, P30CA68485, P30EY08126, and G20RR030956). The contents are solely the responsibility of the authors and do not necessarily represent official views of the funding agencies. |
|
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
Vol 147 - N° 4
P. 1226 - Aprile 2021 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.